ASTELLAS PHARMA

At Astellas, our vision is to be at the forefront of healthcare change by turning innovative science into meaningful VALUE for patients. As a specialty global pharmaceutical company, we focus on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. Together with our partners, we aim to lead in the areas where we can deliver the greatest value, with a focus on immuno-oncology, gene the... rapy, mitochondria, blindness and regeneration and targeted protein degradation. Astellas operates its business in approximately 70 countries around the world. It has approximately 14,000 employees, and its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation. In its FY2022 financial results, revenue achieved about 1,500 billion yen (ca.$11 billion*), and R&D expenses were about 280 billion yen (ca.$2.0 billion*). *The exchange rate for the yen, 1USD: 142yenMore